Other Events ·
GSK announced positive interim results from its phase II AZUR-1 trial for Jemperli (dostarlimab) in patients with…
GSKGSK plc
GSK announced positive interim results from its phase II AZUR-1 trial for Jemperli (dostarlimab) in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer. The single-arm trial met its primary objective, demonstrating a meaningful and sustained clinical complete response rate at 12 months. These results suggest Jemperli could potentially eliminate the need for chemotherapy, radiation, and surgery for some patients. The company plans to share these data with global regulatory authorities to support review, including accelerated review in the US. GSK is a biopharma company that develops medicines and vaccines.